Listed in the December 27, 2023 extract; not in the current extract (Aug 26, 2026): Statex (00591467), Statex (00591475). Source: odb-formulary-ed43-extract-2023-12-27.xml; compared with odb-formulary-ed43-extract-2026-08-26.xml.
MORPHINE SULFATE
Form:
24 of 24 products shown
All strengths: General benefit; same patient cost rules
Shared coverage and patient cost rules
StatusGeneral benefit
Patient paysPatient pays: program not supplied; amount cannot be determined.
Other products in the same Health Canada class (N02A, N02AA) — coverage varies; not interchangeable
Hydromorphone (Hydromorph Contin): general benefit, Not a benefit
Acetylsalicylic acid + butalbital + caffeine + codeine (Fiorinal C1/4): not a benefit
Oxycodone (Supeudol): not a benefit
Acetaminophen + caffeine + codeine (Teva-Lenoltec No.2): general benefit, Not a benefit
Acetaminophen + codeine (PMS-Acetaminophen With Codeine): general benefit, Not a benefit
Acetaminophen + oxycodone (Teva-Oxycocet): general benefit, Not a benefit
Morphine Sulfate Injection USP: Formulary list price $2.2510/unit (unit not stated in source; not the patient's cost)
Ministry pays: $2.2510 per source unit.
Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.
Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=66221 · Verify on the e-Formulary ↗ (DIN 02242484)
Source record
DIN 02242484: Morphine Sulfate Injection USP
Raw flags: sec3=Y
Item: 280808150; group id 408; item number 0992; lccId None; manufacturer id SDZ
Source form: Inj Sol Amp; strength: 2mg/mL
Recorded listing: General benefit
Source prices (unrounded): $2.2510; ministry $2.2510
Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02242484
Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=66221
Shortage status: no shortage or discontinuation reported (checked 2026-09-13T08:10:21.292534+00:00); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02242484
Shortage record checked 2026-09-13T08:10:21.292534+00:00
PMS-Morphine Sulfate · DIN 02549794 · 5mg · tablet
General benefitMarketed · checked 2026-09-02
Write on scriptno code needed
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
1 brand, same coverage
PMS-Morphine Sulfate · DIN 02549794
Manufacturer: Pharmascience Inc.; listing date 2025-02-28
Health Canada: Marketed since 2024-07-29 · brand PMS-MORPHINE SULFATE · ATC N02AA01 MORPHINE · form Tablet · route Oral · ingredients MORPHINE SULFATE 5 MG · company Pharmascience inc · schedule Narcotics (cdsa i)
PMS-Morphine Sulfate: Formulary list price $0.0709/unit (unit not stated in source; not the patient's cost)
Ministry pays: $0.0709 per source unit.
Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.
Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=103861 · Verify on the e-Formulary ↗ (DIN 02549794)
Source record
DIN 02549794: PMS-Morphine Sulfate
Raw flags: sec3=Y
Item: 280808047; group id 408; item number 1007; lccId None; manufacturer id PMS
Source form: Tab; strength: 5mg
Recorded listing: General benefit
Source prices (unrounded): $0.0709; ministry $0.0709
Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02549794
Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=103861Interchangeable products
Statex · DIN 00594652 · $0.0709
Shortage status: no shortage or discontinuation reported (checked 2026-09-13T08:10:21.292534+00:00); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02549794
Shortage record checked 2026-09-13T08:10:21.292534+00:00
Statex · DIN 00594652 · 5mg · tablet
General benefitMarketed · checked 2026-09-02
Write on scriptno code needed
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
1 brand, same coverage
Statex · DIN 00594652
Manufacturer: Knight Therapeutics Inc.; listing date 1996-10-01
Health Canada: Marketed since 2026-03-05 · brand STATEX · ATC N02AA01 MORPHINE · form Tablet · route Oral · ingredients MORPHINE SULFATE 5 MG · company Knight therapeutics inc. · schedule Narcotics (cdsa i)
Statex: Formulary list price $0.0709/unit (unit not stated in source; not the patient's cost)
Ministry pays: $0.0709 per source unit.
Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.
Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=6755 · Verify on the e-Formulary ↗ (DIN 00594652)
Source record
DIN 00594652: Statex
Raw flags: sec3=Y
Item: 280808047; group id 408; item number 1007; lccId None; manufacturer id KNT
Source form: Tab; strength: 5mg
Recorded listing: General benefit
Source prices (unrounded): $0.0709; ministry $0.0709
Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=00594652
Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=6755Interchangeable products
PMS-Morphine Sulfate · DIN 02549794 · $0.0709
Shortage status: resolved shortage (ended 2024-05-01); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=00594652
Shortage record checked 2026-09-13T08:10:21.292534+00:00
M-Eslon · DIN 02019930 · 10mg · extended release capsule
General benefitMarketed · checked 2026-09-02
Write on scriptno code needed
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
No interchangeable product listed in the Ontario extract
M-Eslon · DIN 02019930
Manufacturer: Ethypharm Inc.; listing date 1996-10-01
Health Canada: Marketed since 2006-08-22 · brand M-ESLON · ATC N02AA01 MORPHINE · form Capsule (extended-release) · route Oral · ingredients MORPHINE SULFATE 10 MG · company Ethypharm inc · schedule Narcotics (cdsa i)
M-Eslon: Formulary list price $0.3416/unit (unit not stated in source; not the patient's cost)
Ministry pays: $0.3416 per source unit.
Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.
Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=14543 · Verify on the e-Formulary ↗ (DIN 02019930)
Source record
DIN 02019930: M-Eslon
Raw flags: sec3=Y
Item: 280808068; group id 408; item number 0987; lccId None; manufacturer id ETH
Source form: ER Cap; strength: 10mg
Recorded listing: General benefit
Source prices (unrounded): $0.3416; ministry $0.3416
Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02019930
Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=14543
Shortage status: no shortage or discontinuation reported (checked 2026-09-13T08:10:21.292534+00:00); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02019930
Shortage record checked 2026-09-13T08:10:21.292534+00:00
Morphine Sulfate: Formulary list price $2.3860/unit (unit not stated in source; not the patient's cost)
Ministry pays: $2.3860 per source unit.
Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.
Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=3043 · Verify on the e-Formulary ↗ (DIN 00392588)
Source record
DIN 00392588: Morphine Sulfate
Raw flags: sec3=Y
Item: 280808151; group id 408; item number 0993; lccId None; manufacturer id SDZ
Source form: Inj Sol Amp; strength: 10mg/mL
Recorded listing: General benefit
Source prices (unrounded): $2.3860; ministry $2.3860
Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=00392588
Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=3043
Shortage status: no shortage or discontinuation reported (checked 2026-09-13T08:10:21.292534+00:00); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=00392588
Shortage record checked 2026-09-13T08:10:21.292534+00:00
Kadian · DIN 02242163 · 10mg · extended release capsule
General benefitMarketed · checked 2026-09-02
Write on scriptno code needed
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
No interchangeable product listed in the Ontario extract
Kadian · DIN 02242163
Manufacturer: BGP Pharma ULC; listing date 2003-01-30
Health Canada: Marketed since 2016-05-26 · brand KADIAN · ATC N02AA01 MORPHINE · form Capsule (extended-release) · route Oral · ingredients MORPHINE SULFATE 10 MG · company Bgp pharma ulc · schedule Narcotics (cdsa i)
Kadian: Formulary list price $0.4750/unit (unit not stated in source; not the patient's cost)
Ministry pays: $0.4750 per source unit.
Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.
Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=65841 · Verify on the e-Formulary ↗ (DIN 02242163)
Source record
DIN 02242163: Kadian
Raw flags: sec3=Y
Item: 280808125; group id 408; item number 0996; lccId None; manufacturer id BGP
Source form: SR Cap; strength: 10mg
Recorded listing: General benefit
Source prices (unrounded): $0.4750; ministry $0.4750
Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02242163
Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=65841
Shortage status: resolved shortage (ended 2025-08-11); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02242163
Shortage record checked 2026-09-13T08:10:21.292534+00:00
PMS-Morphine Sulfate · DIN 02549808 · 10mg · tablet
General benefitMarketed · checked 2026-09-02
Write on scriptno code needed
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
1 brand, same coverage
PMS-Morphine Sulfate · DIN 02549808
Manufacturer: Pharmascience Inc.; listing date 2025-02-28
Health Canada: Marketed since 2024-07-29 · brand PMS-MORPHINE SULFATE · ATC N02AA01 MORPHINE · form Tablet · route Oral · ingredients MORPHINE SULFATE 10 MG · company Pharmascience inc · schedule Narcotics (cdsa i)
PMS-Morphine Sulfate: Formulary list price $0.1096/unit (unit not stated in source; not the patient's cost)
Ministry pays: $0.1096 per source unit.
Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.
Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=103862 · Verify on the e-Formulary ↗ (DIN 02549808)
Source record
DIN 02549808: PMS-Morphine Sulfate
Raw flags: sec3=Y
Item: 280808048; group id 408; item number 1008; lccId None; manufacturer id PMS
Source form: Tab; strength: 10mg
Recorded listing: General benefit
Source prices (unrounded): $0.1096; ministry $0.1096
Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02549808
Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=103862Interchangeable products
Statex · DIN 00594644 · $0.1096
Shortage status: no shortage or discontinuation reported (checked 2026-09-13T08:10:21.292534+00:00); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02549808
Shortage record checked 2026-09-13T08:10:21.292534+00:00
Statex · DIN 00594644 · 10mg · tablet
General benefitMarketed · checked 2026-09-02
Write on scriptno code needed
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
1 brand, same coverage
Statex · DIN 00594644
Manufacturer: Knight Therapeutics Inc.; listing date 1996-10-01
Health Canada: Marketed since 2026-03-05 · brand STATEX · ATC N02AA01 MORPHINE · form Tablet · route Oral · ingredients MORPHINE SULFATE 10 MG · company Knight therapeutics inc. · schedule Narcotics (cdsa i)
Statex: Formulary list price $0.1096/unit (unit not stated in source; not the patient's cost)
Ministry pays: $0.1096 per source unit.
Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.
Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=6754 · Verify on the e-Formulary ↗ (DIN 00594644)
Source record
DIN 00594644: Statex
Raw flags: sec3=Y
Item: 280808048; group id 408; item number 1008; lccId None; manufacturer id KNT
Source form: Tab; strength: 10mg
Recorded listing: General benefit
Source prices (unrounded): $0.1096; ministry $0.1096
Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=00594644
Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=6754Interchangeable products
PMS-Morphine Sulfate · DIN 02549808 · $0.1096
Shortage status: resolved shortage (ended 2024-03-27); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=00594644
Shortage record checked 2026-09-13T08:10:21.292534+00:00
M-Eslon · DIN 02177749 · 15mg · extended release capsule
General benefitMarketed · checked 2026-09-02
Write on scriptno code needed
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
No interchangeable product listed in the Ontario extract
M-Eslon · DIN 02177749
Manufacturer: Ethypharm Inc.; listing date 1996-12-19
Health Canada: Marketed since 2006-07-17 · brand M-ESLON · ATC N02AA01 MORPHINE · form Capsule (extended-release) · route Oral · ingredients MORPHINE SULFATE 15 MG · company Ethypharm inc · schedule Narcotics (cdsa i)
M-Eslon: Formulary list price $0.3941/unit (unit not stated in source; not the patient's cost)
Ministry pays: $0.3941 per source unit.
Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.
Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=18878 · Verify on the e-Formulary ↗ (DIN 02177749)
Source record
DIN 02177749: M-Eslon
Raw flags: sec3=Y
Item: 280808086; group id 408; item number 0988; lccId None; manufacturer id ETH
Source form: ER Cap; strength: 15mg
Recorded listing: General benefit
Source prices (unrounded): $0.3941; ministry $0.3941
Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02177749
Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=18878
Shortage status: no shortage or discontinuation reported (checked 2026-09-13T08:10:21.292534+00:00); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02177749
Shortage record checked 2026-09-13T08:10:21.292534+00:00
Morphine Sulfate: Formulary list price $2.0940/unit (unit not stated in source; not the patient's cost)
Ministry pays: $2.0940 per source unit.
Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.
Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=3042 · Verify on the e-Formulary ↗ (DIN 00392561)
Source record
DIN 00392561: Morphine Sulfate
Raw flags: sec3=Y
Item: 280808040; group id 408; item number 0994; lccId None; manufacturer id SDZ
Source form: Inj Sol Amp; strength: 15mg/mL
Recorded listing: General benefit
Source prices (unrounded): $2.0940; ministry $2.0940
Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=00392561
Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=3042Interchangeable products
Morphine Sulfate Injection USP · DIN 00850330 · not recorded
Shortage status: no shortage or discontinuation reported (checked 2026-09-13T08:10:21.292534+00:00); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=00392561
Shortage record checked 2026-09-13T08:10:21.292534+00:00
MS Contin · DIN 02015439 · 15mg · extended release tablet
General benefitMarketed · checked 2026-09-02
Write on scriptno code needed
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
1 brand, same coverage
MS Contin · DIN 02015439
Manufacturer: Purdue Pharma; listing date 1996-10-01
Health Canada: Marketed since 1993-12-31 · brand MS CONTIN · ATC N02AA01 MORPHINE · form Tablet (extended-release) · route Oral · ingredients MORPHINE SULFATE 15 MG · company Purdue pharma · schedule Narcotics (cdsa i)
Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.
Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=14395 · Verify on the e-Formulary ↗ (DIN 02015439)
Source record
DIN 02015439: MS Contin
Raw flags: sec3=Y
Item: 280808053; group id 408; item number 1000; lccId None; manufacturer id PFP
Source form: SR Tab; strength: 15mg
Recorded listing: General benefit
Source prices (unrounded): $1.0086; ministry $0.4145
Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02015439
Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=14395Interchangeable products
Sandoz Morphine SR · DIN 02244790 · $0.4145
Teva-Morphine SR · DIN 02302764 · $0.4145
Shortage status: no shortage or discontinuation reported (checked 2026-09-13T08:10:21.292534+00:00); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02015439
Shortage record checked 2026-09-13T08:10:21.292534+00:00
Sandoz Morphine SR · DIN 02244790 · 15mg · extended release tablet
General benefitMarketed · checked 2026-09-02
Write on scriptno code needed
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims:
6.2 Medically Necessary "No Substitution" Claims
The Side Effect Reporting Form will not have to be renewed. However, the
pharmacy must maintain a copy of the prescription that contains a direction that
there be no substitution and the required Health Canada Side Effect Reporting Form
(completed and signed by the prescriber). The prescriber must write “No
Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and
indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will
be reimbursed the DBP plus a mark-up and the lesser of the posted usual and
customary fee or the ODB dispensing fee minus the applicable ODB co-payment
amount. Where a completed Side Effect Reporting Form is not available at the
pharmacy during an inspection, the difference between the cost of the higher-cost
product and the lowest DBP listed for the interchangeable category will be
recovered.
(ontario.ca, Revision #17; 2026-08-03 ↗)
6.2 Medically Necessary "No Substitution" Claims
The Ministry will provide reimbursement of a higher-cost interchangeable product in
medically necessary circumstances where a patient has experienced a significant
adverse reaction with two (2) lower-cost interchangeable drug products, where
available. When a prescriber identifies a patient for which it is medically necessary
that a higher cost interchangeable product be provided, the prescriber must:
• Complete, sign and forward to the pharmacist a copy of the Health Canada
side effect reporting form for each lower-cost interchangeable drug product
trialed (Side Effect Reporting Form[s]); and
• Write “No Substitution” or “No Sub” on a written prescription or indicate “No
Substitution” to the pharmacist in the case of a verbal prescription.
The prescriber should keep a copy of the completed form in the patient’s record for
future use and reference.
In the case of a written prescription, when the pharmacist or dispensing physician
receives a prescription with the written notation “No Substitution” or “No Sub”,
reimbursement will be provided for the higher-cost interchangeable product only if
the prescription is accompanied by a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed.
This form must be completely filled out noting the details of the adverse reaction
and signed by the prescriber.
In the case of a verbal prescription, the prescriber must satisfy the operator of the
pharmacy or dispensing physician that a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed
has been completed and signed by the prescriber. A written record of this verbal
prescription and the completed Health Canada Side Effect Reporting Form must be
received by the pharmacy prior to claim submission.
Upon receipt, the pharmacist must:
• Fax, submit online or mail the completed and signed form to Health Canada’s
Canada Vigilance Program; and
• Retain his or her copy of the completed and signed Side Effect Reporting
Form.
(ontario.ca, Revision #17; 2026-08-03 ↗)
1 brand, same coverage
Sandoz Morphine SR · DIN 02244790
Manufacturer: Sandoz Canada Inc.; listing date 2002-07-29
Health Canada: Marketed since 2010-12-11 · brand SANDOZ MORPHINE SR · ATC N02AA01 MORPHINE · form Tablet (extended-release) · route Oral · ingredients MORPHINE SULFATE 15 MG · company Sandoz canada incorporated · schedule Narcotics (cdsa i)
Sandoz Morphine SR: Formulary list price $0.4145/unit (unit not stated in source; not the patient's cost)
Ministry pays: $0.4145 per source unit.
Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.
Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=68780 · Verify on the e-Formulary ↗ (DIN 02244790)
Source record
DIN 02244790: Sandoz Morphine SR
Raw flags: sec3=Y
Item: 280808053; group id 408; item number 1000; lccId None; manufacturer id SDZ
Source form: SR Tab; strength: 15mg
Recorded listing: General benefit
Source prices (unrounded): $0.4145; ministry $0.4145
Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02244790
Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=68780Interchangeable products
MS Contin · DIN 02015439 · $0.4145
Teva-Morphine SR · DIN 02302764 · $0.4145
Shortage status: resolved shortage (ended 2025-09-15); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02244790
Shortage record checked 2026-09-13T08:10:21.292534+00:00
Teva-Morphine SR · DIN 02302764 · 15mg · extended release tablet
General benefitMarketed · checked 2026-09-02
Write on scriptno code needed
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims:
6.2 Medically Necessary "No Substitution" Claims
The Side Effect Reporting Form will not have to be renewed. However, the
pharmacy must maintain a copy of the prescription that contains a direction that
there be no substitution and the required Health Canada Side Effect Reporting Form
(completed and signed by the prescriber). The prescriber must write “No
Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and
indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will
be reimbursed the DBP plus a mark-up and the lesser of the posted usual and
customary fee or the ODB dispensing fee minus the applicable ODB co-payment
amount. Where a completed Side Effect Reporting Form is not available at the
pharmacy during an inspection, the difference between the cost of the higher-cost
product and the lowest DBP listed for the interchangeable category will be
recovered.
(ontario.ca, Revision #17; 2026-08-03 ↗)
6.2 Medically Necessary "No Substitution" Claims
The Ministry will provide reimbursement of a higher-cost interchangeable product in
medically necessary circumstances where a patient has experienced a significant
adverse reaction with two (2) lower-cost interchangeable drug products, where
available. When a prescriber identifies a patient for which it is medically necessary
that a higher cost interchangeable product be provided, the prescriber must:
• Complete, sign and forward to the pharmacist a copy of the Health Canada
side effect reporting form for each lower-cost interchangeable drug product
trialed (Side Effect Reporting Form[s]); and
• Write “No Substitution” or “No Sub” on a written prescription or indicate “No
Substitution” to the pharmacist in the case of a verbal prescription.
The prescriber should keep a copy of the completed form in the patient’s record for
future use and reference.
In the case of a written prescription, when the pharmacist or dispensing physician
receives a prescription with the written notation “No Substitution” or “No Sub”,
reimbursement will be provided for the higher-cost interchangeable product only if
the prescription is accompanied by a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed.
This form must be completely filled out noting the details of the adverse reaction
and signed by the prescriber.
In the case of a verbal prescription, the prescriber must satisfy the operator of the
pharmacy or dispensing physician that a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed
has been completed and signed by the prescriber. A written record of this verbal
prescription and the completed Health Canada Side Effect Reporting Form must be
received by the pharmacy prior to claim submission.
Upon receipt, the pharmacist must:
• Fax, submit online or mail the completed and signed form to Health Canada’s
Canada Vigilance Program; and
• Retain his or her copy of the completed and signed Side Effect Reporting
Form.
(ontario.ca, Revision #17; 2026-08-03 ↗)
1 brand, same coverage
Teva-Morphine SR · DIN 02302764
Manufacturer: Teva Canada Limited; listing date 2009-04-01
Health Canada: Marketed since 2011-06-03 · brand TEVA-MORPHINE SR · ATC N02AA01 MORPHINE · form Tablet (extended-release) · route Oral · ingredients MORPHINE SULFATE 15 MG · company Teva canada limited · schedule Narcotics (cdsa i)
Teva-Morphine SR: Formulary list price $0.4145/unit (unit not stated in source; not the patient's cost)
Ministry pays: $0.4145 per source unit.
Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.
Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=78808 · Verify on the e-Formulary ↗ (DIN 02302764)
Source record
DIN 02302764: Teva-Morphine SR
Raw flags: sec3=Y
Item: 280808053; group id 408; item number 1000; lccId None; manufacturer id TEV
Source form: SR Tab; strength: 15mg
Recorded listing: General benefit
Source prices (unrounded): $0.4145; ministry $0.4145
Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02302764
Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=78808Interchangeable products
MS Contin · DIN 02015439 · $0.4145
Sandoz Morphine SR · DIN 02244790 · $0.4145
Shortage status: resolved shortage (ended 2025-08-07); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02302764
Shortage record checked 2026-09-13T08:10:21.292534+00:00
Kadian · DIN 02184435 · 20mg · extended release capsule
General benefitMarketed · checked 2026-09-02
Write on scriptno code needed
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
No interchangeable product listed in the Ontario extract
Kadian · DIN 02184435
Manufacturer: BGP Pharma ULC; listing date 1997-08-28
Health Canada: Marketed since 2016-05-26 · brand KADIAN · ATC N02AA01 MORPHINE · form Capsule (extended-release) · route Oral · ingredients MORPHINE SULFATE 20 MG · company Bgp pharma ulc · schedule Narcotics (cdsa i)
Kadian: Formulary list price $0.9228/unit (unit not stated in source; not the patient's cost)
Ministry pays: $0.9228 per source unit.
Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.
Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=42846 · Verify on the e-Formulary ↗ (DIN 02184435)
Source record
DIN 02184435: Kadian
Raw flags: sec3=Y
Item: 280808093; group id 408; item number 0997; lccId None; manufacturer id BGP
Source form: SR Cap; strength: 20mg
Recorded listing: General benefit
Source prices (unrounded): $0.9228; ministry $0.9228
Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02184435
Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=42846
Shortage status: resolved shortage (ended 2025-08-11); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02184435
Shortage record checked 2026-09-13T08:10:21.292534+00:00
MS-IR · DIN 02014238 · 20mg · tablet
General benefitMarketed · checked 2026-09-02
Write on scriptno code needed
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
No interchangeable product listed in the Ontario extract
MS-IR · DIN 02014238
Manufacturer: Purdue Pharma; listing date 1996-10-01
Health Canada: Marketed since 1991-12-31 · brand MS.IR · ATC N02AA01 MORPHINE · form Tablet (immediate-release) · route Oral · ingredients MORPHINE SULFATE 20 MG · company Purdue pharma · schedule Narcotics (cdsa i)
MS-IR: Formulary list price $0.4702/unit (unit not stated in source; not the patient's cost)
Ministry pays: $0.4702 per source unit.
Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.
Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=16480 · Verify on the e-Formulary ↗ (DIN 02014238)
Source record
DIN 02014238: MS-IR
Raw flags: sec3=Y
Item: 280808051; group id 408; item number 1005; lccId None; manufacturer id PFP
Source form: Tab; strength: 20mg
Recorded listing: General benefit
Source prices (unrounded): $0.4702; ministry $0.4702
Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02014238
Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=16480
Shortage status: resolved shortage (ended 2023-01-23); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02014238
Shortage record checked 2026-09-13T08:10:21.292534+00:00
M-Eslon · DIN 02019949 · 30mg · extended release capsule
General benefitMarketed · checked 2026-09-02
Write on scriptno code needed
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
No interchangeable product listed in the Ontario extract
M-Eslon · DIN 02019949
Manufacturer: Ethypharm Inc.; listing date 1996-10-01
Health Canada: Marketed since 2006-08-07 · brand M-ESLON · ATC N02AA01 MORPHINE · form Capsule (extended-release) · route Oral · ingredients MORPHINE SULFATE 30 MG · company Ethypharm inc · schedule Narcotics (cdsa i)
M-Eslon: Formulary list price $0.5875/unit (unit not stated in source; not the patient's cost)
Ministry pays: $0.5875 per source unit.
Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.
Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=14502 · Verify on the e-Formulary ↗ (DIN 02019949)
Source record
DIN 02019949: M-Eslon
Raw flags: sec3=Y
Item: 280808069; group id 408; item number 0989; lccId None; manufacturer id ETH
Source form: ER Cap; strength: 30mg
Recorded listing: General benefit
Source prices (unrounded): $0.5875; ministry $0.5875
Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02019949
Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=14502
Shortage status: no shortage or discontinuation reported (checked 2026-09-13T08:10:21.292534+00:00); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02019949
Shortage record checked 2026-09-13T08:10:21.292534+00:00
MS Contin · DIN 02014297 · 30mg · extended release tablet
General benefitMarketed · checked 2026-09-02
Write on scriptno code needed
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
1 brand, same coverage
MS Contin · DIN 02014297
Manufacturer: Purdue Pharma; listing date 1996-10-01
Health Canada: Marketed since 1993-12-31 · brand MS CONTIN · ATC N02AA01 MORPHINE · form Tablet (extended-release) · route Oral · ingredients MORPHINE SULFATE 30 MG · company Purdue pharma · schedule Narcotics (cdsa i)
Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.
Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=14176 · Verify on the e-Formulary ↗ (DIN 02014297)
Source record
DIN 02014297: MS Contin
Raw flags: sec3=Y
Item: 280808054; group id 408; item number 1001; lccId None; manufacturer id PFP
Source form: SR Tab; strength: 30mg
Recorded listing: General benefit
Source prices (unrounded): $1.5245; ministry $0.6580
Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02014297
Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=14176Interchangeable products
Sandoz Morphine SR · DIN 02244791 · $0.6580
Teva-Morphine SR · DIN 02302772 · $0.6580
Shortage status: resolved shortage (ended 2022-12-07); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02014297
Shortage record checked 2026-09-13T08:10:21.292534+00:00
Sandoz Morphine SR · DIN 02244791 · 30mg · extended release tablet
General benefitMarketed · checked 2026-09-02
Write on scriptno code needed
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims:
6.2 Medically Necessary "No Substitution" Claims
The Side Effect Reporting Form will not have to be renewed. However, the
pharmacy must maintain a copy of the prescription that contains a direction that
there be no substitution and the required Health Canada Side Effect Reporting Form
(completed and signed by the prescriber). The prescriber must write “No
Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and
indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will
be reimbursed the DBP plus a mark-up and the lesser of the posted usual and
customary fee or the ODB dispensing fee minus the applicable ODB co-payment
amount. Where a completed Side Effect Reporting Form is not available at the
pharmacy during an inspection, the difference between the cost of the higher-cost
product and the lowest DBP listed for the interchangeable category will be
recovered.
(ontario.ca, Revision #17; 2026-08-03 ↗)
6.2 Medically Necessary "No Substitution" Claims
The Ministry will provide reimbursement of a higher-cost interchangeable product in
medically necessary circumstances where a patient has experienced a significant
adverse reaction with two (2) lower-cost interchangeable drug products, where
available. When a prescriber identifies a patient for which it is medically necessary
that a higher cost interchangeable product be provided, the prescriber must:
• Complete, sign and forward to the pharmacist a copy of the Health Canada
side effect reporting form for each lower-cost interchangeable drug product
trialed (Side Effect Reporting Form[s]); and
• Write “No Substitution” or “No Sub” on a written prescription or indicate “No
Substitution” to the pharmacist in the case of a verbal prescription.
The prescriber should keep a copy of the completed form in the patient’s record for
future use and reference.
In the case of a written prescription, when the pharmacist or dispensing physician
receives a prescription with the written notation “No Substitution” or “No Sub”,
reimbursement will be provided for the higher-cost interchangeable product only if
the prescription is accompanied by a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed.
This form must be completely filled out noting the details of the adverse reaction
and signed by the prescriber.
In the case of a verbal prescription, the prescriber must satisfy the operator of the
pharmacy or dispensing physician that a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed
has been completed and signed by the prescriber. A written record of this verbal
prescription and the completed Health Canada Side Effect Reporting Form must be
received by the pharmacy prior to claim submission.
Upon receipt, the pharmacist must:
• Fax, submit online or mail the completed and signed form to Health Canada’s
Canada Vigilance Program; and
• Retain his or her copy of the completed and signed Side Effect Reporting
Form.
(ontario.ca, Revision #17; 2026-08-03 ↗)
1 brand, same coverage
Sandoz Morphine SR · DIN 02244791
Manufacturer: Sandoz Canada Inc.; listing date 2002-07-29
Health Canada: Marketed since 2010-12-11 · brand SANDOZ MORPHINE SR · ATC N02AA01 MORPHINE · form Tablet (extended-release) · route Oral · ingredients MORPHINE SULFATE 30 MG · company Sandoz canada incorporated · schedule Narcotics (cdsa i)
Sandoz Morphine SR: Formulary list price $0.6580/unit (unit not stated in source; not the patient's cost)
Ministry pays: $0.6580 per source unit.
Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.
Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=68781 · Verify on the e-Formulary ↗ (DIN 02244791)
Source record
DIN 02244791: Sandoz Morphine SR
Raw flags: sec3=Y
Item: 280808054; group id 408; item number 1001; lccId None; manufacturer id SDZ
Source form: SR Tab; strength: 30mg
Recorded listing: General benefit
Source prices (unrounded): $0.6580; ministry $0.6580
Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02244791
Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=68781Interchangeable products
MS Contin · DIN 02014297 · $0.6580
Teva-Morphine SR · DIN 02302772 · $0.6580
Shortage status: resolved shortage (ended 2023-02-08); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02244791
Shortage record checked 2026-09-13T08:10:21.292534+00:00
Teva-Morphine SR · DIN 02302772 · 30mg · extended release tablet
General benefitMarketed · checked 2026-09-02
Write on scriptno code needed
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims:
6.2 Medically Necessary "No Substitution" Claims
The Side Effect Reporting Form will not have to be renewed. However, the
pharmacy must maintain a copy of the prescription that contains a direction that
there be no substitution and the required Health Canada Side Effect Reporting Form
(completed and signed by the prescriber). The prescriber must write “No
Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and
indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will
be reimbursed the DBP plus a mark-up and the lesser of the posted usual and
customary fee or the ODB dispensing fee minus the applicable ODB co-payment
amount. Where a completed Side Effect Reporting Form is not available at the
pharmacy during an inspection, the difference between the cost of the higher-cost
product and the lowest DBP listed for the interchangeable category will be
recovered.
(ontario.ca, Revision #17; 2026-08-03 ↗)
6.2 Medically Necessary "No Substitution" Claims
The Ministry will provide reimbursement of a higher-cost interchangeable product in
medically necessary circumstances where a patient has experienced a significant
adverse reaction with two (2) lower-cost interchangeable drug products, where
available. When a prescriber identifies a patient for which it is medically necessary
that a higher cost interchangeable product be provided, the prescriber must:
• Complete, sign and forward to the pharmacist a copy of the Health Canada
side effect reporting form for each lower-cost interchangeable drug product
trialed (Side Effect Reporting Form[s]); and
• Write “No Substitution” or “No Sub” on a written prescription or indicate “No
Substitution” to the pharmacist in the case of a verbal prescription.
The prescriber should keep a copy of the completed form in the patient’s record for
future use and reference.
In the case of a written prescription, when the pharmacist or dispensing physician
receives a prescription with the written notation “No Substitution” or “No Sub”,
reimbursement will be provided for the higher-cost interchangeable product only if
the prescription is accompanied by a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed.
This form must be completely filled out noting the details of the adverse reaction
and signed by the prescriber.
In the case of a verbal prescription, the prescriber must satisfy the operator of the
pharmacy or dispensing physician that a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed
has been completed and signed by the prescriber. A written record of this verbal
prescription and the completed Health Canada Side Effect Reporting Form must be
received by the pharmacy prior to claim submission.
Upon receipt, the pharmacist must:
• Fax, submit online or mail the completed and signed form to Health Canada’s
Canada Vigilance Program; and
• Retain his or her copy of the completed and signed Side Effect Reporting
Form.
(ontario.ca, Revision #17; 2026-08-03 ↗)
1 brand, same coverage
Teva-Morphine SR · DIN 02302772
Manufacturer: Teva Canada Limited; listing date 2009-06-23
Health Canada: Marketed since 2011-06-03 · brand TEVA-MORPHINE SR · ATC N02AA01 MORPHINE · form Tablet (extended-release) · route Oral · ingredients MORPHINE SULFATE 30 MG · company Teva canada limited · schedule Narcotics (cdsa i)
Teva-Morphine SR: Formulary list price $0.6580/unit (unit not stated in source; not the patient's cost)
Ministry pays: $0.6580 per source unit.
Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.
Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=78809 · Verify on the e-Formulary ↗ (DIN 02302772)
Source record
DIN 02302772: Teva-Morphine SR
Raw flags: sec3=Y
Item: 280808054; group id 408; item number 1001; lccId None; manufacturer id TEV
Source form: SR Tab; strength: 30mg
Recorded listing: General benefit
Source prices (unrounded): $0.6580; ministry $0.6580
Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02302772
Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=78809Interchangeable products
MS Contin · DIN 02014297 · $0.6580
Sandoz Morphine SR · DIN 02244791 · $0.6580
Shortage status: resolved shortage (ended 2026-07-31); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02302772
Shortage record checked 2026-09-13T08:10:21.292534+00:00
MS-IR · DIN 02014254 · 30mg · tablet
General benefitMarketed · checked 2026-09-02
Write on scriptno code needed
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
No interchangeable product listed in the Ontario extract
MS-IR · DIN 02014254
Manufacturer: Purdue Pharma; listing date 1996-10-01
Health Canada: Marketed since 1991-12-31 · brand MS.IR · ATC N02AA01 MORPHINE · form Tablet (immediate-release) · route Oral · ingredients MORPHINE SULFATE 30 MG · company Purdue pharma · schedule Narcotics (cdsa i)
MS-IR: Formulary list price $0.6036/unit (unit not stated in source; not the patient's cost)
Ministry pays: $0.6036 per source unit.
Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.
Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=16481 · Verify on the e-Formulary ↗ (DIN 02014254)
Source record
DIN 02014254: MS-IR
Raw flags: sec3=Y
Item: 280808052; group id 408; item number 1006; lccId None; manufacturer id PFP
Source form: Tab; strength: 30mg
Recorded listing: General benefit
Source prices (unrounded): $0.6036; ministry $0.6036
Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02014254
Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=16481
Shortage status: resolved shortage (ended 2021-05-28); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02014254
Shortage record checked 2026-09-13T08:10:21.292534+00:00
Morphine HP-50: Formulary list price $6.8195/unit (unit not stated in source; not the patient's cost)
Ministry pays: $6.8195 per source unit.
Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.
Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=7421 · Verify on the e-Formulary ↗ (DIN 00617288)
Source record
DIN 00617288: Morphine HP-50
Raw flags: sec3=Y
Item: 280808041; group id 408; item number 0995; lccId None; manufacturer id SDZ
Source form: Inj Sol-1mL Pk; strength: 50mg/mL
Recorded listing: General benefit
Source prices (unrounded): $6.8195; ministry $6.8195
Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=00617288
Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=7421
Shortage status: resolved shortage (ended 2023-02-27); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=00617288
Shortage record checked 2026-09-13T08:10:21.292534+00:00
Kadian · DIN 02184443 · 50mg · extended release capsule
General benefitMarketed · checked 2026-09-02
Write on scriptno code needed
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
No interchangeable product listed in the Ontario extract
Kadian · DIN 02184443
Manufacturer: BGP Pharma ULC; listing date 1997-08-28
Health Canada: Marketed since 2016-05-26 · brand KADIAN · ATC N02AA01 MORPHINE · form Capsule (extended-release) · route Oral · ingredients MORPHINE SULFATE 50 MG · company Bgp pharma ulc · schedule Narcotics (cdsa i)
Kadian: Formulary list price $1.7456/unit (unit not stated in source; not the patient's cost)
Ministry pays: $1.7456 per source unit.
Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.
Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=42847 · Verify on the e-Formulary ↗ (DIN 02184443)
Source record
DIN 02184443: Kadian
Raw flags: sec3=Y
Item: 280808094; group id 408; item number 0998; lccId None; manufacturer id BGP
Source form: SR Cap; strength: 50mg
Recorded listing: General benefit
Source prices (unrounded): $1.7456; ministry $1.7456
Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02184443
Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=42847
Shortage status: resolved shortage (ended 2025-08-11); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02184443
Shortage record checked 2026-09-13T08:10:21.292534+00:00
M-Eslon · DIN 02019957 · 60mg · extended release capsule
General benefitMarketed · checked 2026-09-02
Write on scriptno code needed
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
No interchangeable product listed in the Ontario extract
M-Eslon · DIN 02019957
Manufacturer: Ethypharm Inc.; listing date 1996-10-01
Health Canada: Marketed since 2006-07-31 · brand M-ESLON · ATC N02AA01 MORPHINE · form Capsule (extended-release) · route Oral · ingredients MORPHINE SULFATE 60 MG · company Ethypharm inc · schedule Narcotics (cdsa i)
M-Eslon: Formulary list price $1.0457/unit (unit not stated in source; not the patient's cost)
Ministry pays: $1.0457 per source unit.
Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.
Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=14542 · Verify on the e-Formulary ↗ (DIN 02019957)
Source record
DIN 02019957: M-Eslon
Raw flags: sec3=Y
Item: 280808070; group id 408; item number 0990; lccId None; manufacturer id ETH
Source form: ER Cap; strength: 60mg
Recorded listing: General benefit
Source prices (unrounded): $1.0457; ministry $1.0457
Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02019957
Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=14542
Shortage status: resolved shortage (ended 2018-03-14); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02019957
Shortage record checked 2026-09-13T08:10:21.292534+00:00
MS Contin · DIN 02014300 · 60mg · extended release tablet
General benefitMarketed · checked 2026-09-02
Write on scriptno code needed
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
1 brand, same coverage
MS Contin · DIN 02014300
Manufacturer: Purdue Pharma; listing date 1996-10-01
Health Canada: Marketed since 1993-12-31 · brand MS CONTIN · ATC N02AA01 MORPHINE · form Tablet (extended-release) · route Oral · ingredients MORPHINE SULFATE 60 MG · company Purdue pharma · schedule Narcotics (cdsa i)
Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.
Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=14394 · Verify on the e-Formulary ↗ (DIN 02014300)
Source record
DIN 02014300: MS Contin
Raw flags: sec3=Y
Item: 280808055; group id 408; item number 1002; lccId None; manufacturer id PFP
Source form: SR Tab; strength: 60mg
Recorded listing: General benefit
Source prices (unrounded): $2.6874; ministry $1.2180
Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02014300
Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=14394Interchangeable products
Sandoz Morphine SR · DIN 02244792 · $1.2180
Teva-Morphine SR · DIN 02302780 · $1.2180
Shortage status: resolved shortage (ended 2026-03-10); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02014300
Shortage record checked 2026-09-13T08:10:21.292534+00:00
Other drugs in the same formulary class (28:08:08 Opiate Agonists) and how they are covered
Matched class: 28:08:08 Opiate Agonists
Drug-class inventory only. Lists recorded Ontario formulary products, not every Canadian medication; does not recommend treatment.
Some products covered without a code (check the product listing): ACETAMINOPHEN & CAFFEINE & CODEINE PHOSPHATE, ACETAMINOPHEN & CODEINE PHOSPHATE, CODEINE PHOSPHATE, HYDROMORPHONE HCL, METHADONE HCL, OXYCODONE HCL & ACETAMINOPHEN, OXYCODONE HCL & ACETYLSALICYLIC ACID
28:08:08 Opiate Agonists
INDICATIONS AND CLINICAL USE
Adults
Morphine Sulfate Injection USP, administered by slow intravenous injection, is indicated
exclusively for the symptomatic relief of moderate to severe pain.
Morphine Sulfate Injection USP is not indicated as an as-needed (prn) analgesic.
Geriatrics (> 65 years of age)
In general, dose selection for an elderly patient should be cautious, usually starting at the low end
of the dosing range, reflecting the greater frequency of decreased hepatic, renal, or cardiac
function, concomitant disease or other drug therapy.
Pediatrics (< 12years of age)
The safety and efficacy of morphine sulfate has not been studied in the pediatric population.
N
Morphine Sulfate Injection USP Page 3 of 33
Therefore the use of Morphine Sulfate Injection USP is not recommended in patients under 12
years of age.
https://pdf.hres.ca/dpd_pm/00057801.PDF
PM date: July 15, 2020
Source product: MORPHINE SULFATE INJ 15MG/ML USP; DIN 00392561; fetched 2026-09-10
Product monograph posted by Health Canada; excerpt for lookup only.
Prepare an Exceptional Access request
SADIE has its own form for many drugs; this checklist prepares the answers; the ministry decides. Open SADIE
Use this text in SADIE’s free-text fields or read from it on a Telephone Request Service call. Review marks do not indicate eligibility. Evidence stays in this page until you copy it; nothing entered here is sent or saved. Do not enter patient identifiers.
EAP Telephone Request Service: The TRS can be accessed by calling toll-free at 1-866-811-9893 or 416-327-8109 (Toronto area) between 8:30 a.m. and 5:00 p.m. Monday through Friday (except holidays) and selecting the TRS option. Source; updated September 15, 2026
Posted turnaround and Telephone Request Service scope
Turnaround times
The Exceptional Access Program receives between 250 and 500 requests a day. Requests are categorized in order of priority based on how quickly a drug is needed, the type of drug, and the condition for which the drug is being used.
Turnaround times begin on the business day on which the EAP receives a complete request from a physician or nurse practitioner. You may have to wait longer if the request is missing information or supporting documents required by the EAP criteria, if a request requires external review, or if documents are sent by fax or mail instead of submitted via SADIE.
EAP Weekly Progress Report
Date: September 15, 2026
Processing categories and examples | Target | Current |
Priority 1 — for drugs such as antibiotics, cancer medications, and initial requests for pain medications | 3 business days | 2 business day |
Priority 2 — for antiviral drugs to treat HIV, drugs for multiple sclerosis, and pulmonary hypertension | 5 business days | 3 business days |
Biologics — for biologic drugs to treat rheumatoid arthritis, psoriatic arthritis, ulcerative colitis and Crohn’s disease | 10 business days | 4 business days |
Chronic — for drugs used for chronic conditions such as migraines, chronic pain, Ménière's disease and symptoms of Parkinson’s disease. | 4 to 6 weeks | 11 business days |
For selected drugs, the Telephone Request Service is available to authorized prescribers or their delegates. In most cases, the funding decision is provided by the end of the call and processed within one business day.
Ministry criteria list dated January 1, 2025; the program's current criteria may differ; SADIE shows the current version. Current criteria in SADIE
Prepare answers: For use in a palliative patient requiring oral liquid morphine. Doloral oral liquid products are
interim/temporary listing authorized by the Executive Officer as oral liquid morphine
products on the formulary were withdrawn from the market by the manufacturer.
For use in a palliative patient requiring oral liquid morphine. Doloral oral liquid products are
interim/temporary listing authorized by the Executive Officer as oral liquid morphine
products on the formulary were withdrawn from the market by the manufacturer.
Prepared from the ministry's published criteria; eligibility is decided by the Exceptional Access Program.